Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy Gregg W. Stone, MD, Herbert D. Aronow, MD, MPH Mayo Clinic Proceedings Volume 81, Issue 5, Pages 641-652 (May 2006) DOI: 10.4065/81.5.641 Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions
FIGURE 1 Factors involved in platelet aggregation and the points of action (parallel lines) of various antithrombotic and anticoagulant drugs. ADP = adenosine diphosphate; LMWHs = low-molecular-weight heparins; UFH = unfractionated heparin. From Am J Cardiovasc Drugs,10 with permission from Wolters Kluwer Health. Mayo Clinic Proceedings 2006 81, 641-652DOI: (10.4065/81.5.641) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions
FIGURE 2 Mechanisms of action of antiplatelet drugs and the routes to inhibiting platelet function. ADP = adenosine diphosphate; GP = glycoprotein. From BMJ,53 with permission from BMJ Publishing Group Ltd. Mayo Clinic Proceedings 2006 81, 641-652DOI: (10.4065/81.5.641) Copyright © 2006 Mayo Foundation for Medical Education and Research Terms and Conditions